Model shows early detection can reduce injury severity and deliver millions in annual margin impact for hospitals

模型显示，早期检测可以减轻损伤严重程度，并为医院带来数百万的年度利润影响。

NEWPORT NEWS, Va.

纽波特纽斯，弗吉尼亚州

,

，

March 10, 2026

2026年3月10日

/PRNewswire/ -- ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these events earlier..

/PRNewswire/ -- 静脉注射安全公司ivWatch已与全球领先的保险经纪和风险咨询公司Aon合作，量化严重静脉注射渗漏和外渗损伤的临床和财务影响——这是医疗保健领域中最少报告且成本最高的不良事件之一——并模拟通过早期检测这些事件所带来的投资回报。

Continue Reading

继续阅读

ivWatch continuous patient monitoring for early detection of IV extravasation and infiltration events.

ivWatch持续患者监测，用于早期检测静脉输液外渗和浸润事件。

Aon used multiple types of proprietary data, including the largest database of information on healthcare professional liability claims and true costs of providing healthcare services to quantify the downstream financial consequences hospitals face when IV injuries escalate, including uncompensated remedial care, professional liability exposure, workflow disruption, and patient satisfaction penalties.

怡安使用了多种类型的专有数据，包括关于医疗保健专业责任索赔和提供医疗服务的真实成本的最大数据库，以量化医院在静脉输液伤害升级时面临的下游财务后果，包括未补偿的补救护理、职业责任风险、工作流程中断和患者满意度处罚。

The model demonstrates that early detection through continuous IV monitoring significantly reduces patient harm and helps prevent severe IV injuries from becoming costly and clinically problematic for hospitals..

该模型表明，通过持续的静脉注射监测进行早期检测，可显著减少患者伤害，并有助于防止严重的静脉注射损伤变得昂贵且在临床上令医院棘手。

IV injuries develop silently and are frequently unrecognized, misdiagnosed, or inadequately reported until they progress to severe outcomes. A recent large retrospective study published in the

四级损伤悄无声息地发展，经常未被识别、误诊或报告不足，直到进展为严重后果。最近发表在某期刊上的一项大型回顾性研究指出。

British Medical Journal

英国医学期刊

analyzed the use of ivWatch technology in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) compared with conventional observed methods. The study showed a 93% reduction in the severity of IV injuries when continuous sensor-based monitoring was used.

分析了ivWatch技术在早期检测外周静脉渗漏或外渗（PIVIE）方面与传统观察方法的对比应用。研究表明，使用连续传感器监测可使静脉输液损伤的严重程度减少93%。

When identified too late, IV injuries can result in serious patient harm, including skin necrosis, scarring and staining, nerve damage, medication dosing errors, and, in extreme cases, amputation.

如果发现得太晚，静脉输液损伤可能会导致严重的患者伤害，包括皮肤坏死、疤痕和色素沉着、神经损伤、药物剂量错误，极端情况下甚至需要截肢。

By combining the strong clinical efficacy of ivWatch with Aon's proprietary healthcare liability, cost, claims, and hospital benchmarking data, the analysis evaluated the expected outcomes of implementing ivWatch in both pediatric and non-pediatric hospital settings. The model highlights the often-unaccounted-for financial consequences of IV extravasation events, including professional liability exposure and uncompensated care, as well as patient satisfaction and reliance on central lines..

通过将ivWatch强大的临床疗效与Aon专有的医疗责任、成本、索赔和医院基准数据相结合，该分析评估了在儿科和非儿科医院环境中实施ivWatch的预期结果。该模型强调了静脉输液外渗事件经常被忽视的财务后果，包括职业责任风险和未补偿的护理，以及患者满意度和对中心静脉导管的依赖。

According to the validated model, preventing severe extravasation events could translate into annual margin impacts of $8.9 million to $13.4 million for a 150-bed pediatric hospital and $5.1 million to $7.9 million for non-pediatric hospitals. Even using conservative assumptions, the analysis shows return of roughly 7x to 14x..

根据已验证的模型，预防严重的外渗事件可为一家拥有150张床位的儿科医院带来每年890万至1340万美元的利润影响，而对于非儿科医院，则可能带来510万至790万美元的影响。即使采用保守假设，分析也显示回报率大约为7倍至14倍。

'IV extravasations represent a significant source of risk and downstream costs for hospitals, and that risk is often underestimated or goes uncalculated altogether,' said John Rudoy, healthcare industry practice leader at Aon. 'When those costs are finally quantified, it becomes clear that severe IV injuries drain millions from hospital margins every year and that earlier detection can significantly reduce that exposure.'.

“静脉输液外渗是医院面临的一个重大风险源和下游成本，而这种风险往往被低估或完全未被计算，”怡安公司医疗行业实践负责人约翰·鲁多伊表示。“当这些成本最终被量化时，就会清楚地发现，严重的静脉输液损伤每年都会使医院利润减少数百万美元，而早期检测则可以显著降低这种风险。”

The findings also highlight substantial potential savings from preventing the costly follow-up care hospitals often absorb, including surgical interventions, extended hospital stays, and ICU days. Aon estimates that reducing this unreimbursed care alone could improve hospital margins by $1.6 million to $5.6 million annually, depending on patient population and payer mix..

研究结果还强调了预防医院常常承担的昂贵后续护理所带来的巨大潜在节省，这些护理包括手术干预、住院时间延长和重症监护室（ICU）天数。怡安（Aon）估计，仅减少这部分未报销的护理，就可以使医院的利润每年提高160万至560万美元，具体取决于患者群体和支付方组合。

'When serious IV injuries occur, hospitals are often blindsided by a cascade of clinical and financial challenges,' said ivWatch President Erin Wendell. 'What starts as a routine procedure can quickly escalate into catastrophic outcomes for patients, clinicians, and healthcare institutions. These events are largely preventable with proven technology that delivers better patient care and a significant return on investment.'.

“当严重的静脉注射损伤发生时，医院常常会面临一系列临床和财务挑战的突袭，”ivWatch总裁Erin Wendell说道。“起初看似常规的操作可能迅速演变成对患者、临床医生和医疗机构的灾难性后果。通过经过验证的技术，这些事件大多是可以预防的，该技术不仅能提供更好的患者护理，还能带来显著的投资回报。”

Beyond direct cost avoidance, the model also accounts for workflow disruption caused by increased readmissions, extended lengths of stay, and the need for additional clinical resources. Reduced legal exposure, including lower cost judgments, lower legal costs, lower insurance premiums, and fewer judgments, results in immediate annual savings.

除了直接的成本规避，该模型还考虑了因再入院率增加、住院时间延长以及对额外临床资源需求所导致的工作流程中断。降低法律风险，包括减少赔偿金额、降低法律费用、减少保险费和判决数量，从而带来立竿见影的年度节省。

In addition, patients who do not experience complications are twice as likely to give a top satisfaction rating, and for every 10% improvement in top ratings, hospitals see an estimated 1.5% improvement in revenue..

此外，没有出现并发症的患者给出最高满意度评价的可能性是其他患者的两倍，并且每提升10%的最高评价，医院的收入预计会增加1.5%。

Aon exists to shape decisions for the better. Through actionable analytic insight, globally integrated risk capital and human capital expertise and locally relevant solutions, Aon provides clients in over 120 countries with the clarity to make better risk and people decisions. Aon works specifically within the healthcare industry to help health systems meet the future by managing the increasingly complex risks they face while optimizing their revenue models..

Aon致力于做出更好的决策。通过可操作的分析洞察、全球整合的风险资本和人力资源专业知识，以及本地相关的解决方案，Aon为遍布120多个国家的客户提供清晰的视角，以做出更明智的风险和人员决策。Aon特别在医疗保健行业内工作，帮助卫生系统通过管理日益复杂的风险来迎接未来，同时优化其收入模式。

ivWatch continuously monitors IV sites and alerts clinicians when early signs of infiltration or extravasation are detected, allowing intervention before injuries escalate. The technology uses near-infrared light and a predictive algorithm, holds nearly 70 patents globally, and is the only FDA-cleared and CE-marked solution proven to help reduce IV injury severity through continuous monitoring..

ivWatch持续监测静脉注射部位，并在发现渗漏或外渗的早期迹象时向临床医生发出警报，以便在伤害加重前进行干预。该技术使用近红外光和预测算法，在全球拥有近70项专利，是唯一通过FDA认证和CE标志的解决方案，被证明可以通过持续监测帮助减轻静脉注射损伤的严重程度。

The full ivWatch Aon Value Estimation white paper is available to view and

完整的ivWatch Aon价值评估白皮书可供查看和

download

下载

.

。

About ivWatch:

关于ivWatch：

ivWatch is changing IV safety. IV insertion is the most common hospital procedure, yet up to 50% fail, often with severe consequences ranging from dosing errors, scarring, skin staining, nerve damage, amputation, and even death. Founded in 2010 and holding nearly 70 patents, ivWatch has developed a first-of-its-kind FDA-cleared Class II medical device that continuously monitors peripheral IVs to aid in the early detection of infiltration and extravasation events.

ivWatch 正在改变静脉注射安全。静脉注射是医院最常见的操作，但高达 50% 的注射可能会失败，往往带来严重后果，包括剂量错误、疤痕、皮肤染色、神经损伤、截肢甚至死亡。ivWatch 成立于 2010 年，拥有近 70 项专利，开发了首个获得 FDA 批准的 II 类医疗设备，可持续监测外周静脉注射，帮助早期发现渗漏和外渗事件。

To learn more, visit .

要了解更多信息，请访问。

www.ivwatch.com

www.ivwatch.com

.

。

About Aon:

关于Aon：

Aon plc exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses..

Aon plc致力于做出更好的决策——保护和丰富全球人民的生活。通过可操作的分析洞察、全球整合的风险资本和人力资本专业知识，以及本地相关的解决方案，我们在120多个国家的同事为客户提供清晰和信心，以做出更好的风险和人员决策，保护和发展他们的业务。

SOURCE ivWatch, LLC

来源 ivWatch, LLC

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示